Proteina Co Ltd

Proteina Co., Ltd. is dedicated to pioneering technology for characterizing protein-protein interactions (PPIs). Their innovative approach enables the direct visualization of specific proteins to confirm the real-time activation of cancer signaling pathways. This capability helps predict drug efficacy and, crucially, empowers medical professionals to select optimal inhibitors by identifying bypass pathways that contribute to drug resistance. The company further offers a distinct single-molecule protein interaction detection platform, designed for in-depth analysis of protein and PPI information. Founded in 2015, Proteina Co., Ltd. is headquartered in Seoul, South Korea.